Manufacturing Site #1 (Ambernath, India)
Rubicon Research’s world-class Ambernath plant is focused on producing pharmaceutical products (Rx as well as over the counter), and supports scale up and commercialization in a range of oral solids.
The 140,000+ square feet state-of-the-art manufacturing plant is compliant with US FDA and EU specifications, with 43,500 square feet of the entire area specially devoted to cGMP manufacturing. It has capabilities across powders, granules, pellets, dispersible tablets, orally disintegrating tablets, controlled/modified release tablets and hard gelatin capsules.
|Capacity (Million Units)||Current||By Q2 2020|
Manufacturing Site #2 (Satara, India)
Part of the Rubicon Research Network since 2021, the Satara plant is focussed on producing oral-liquid pharmaceutical products. This plant can produce non-sterile oral solutions and suspensions and supports packaging in a variety of formats.
The 50,000+ square feet manufacturing plant is compliant with global regulatory standards and is currently inspected by and in good standing with the UK-MHRA among other global regulatory bodies.
Rubicon Research intends to register products with the USFDA and trigger an inspection by the agency in early 2022.
Key highlights include:
To request for our equipment list, drop us an email at firstname.lastname@example.org